Clinical and economic analysis of the modern strategies for treating metabolic syndrome

Objective. The objective of this study was to identify the ways to optimize therapy for metabolic syndrome through complex clinical and economic analysis. Methods. Sixty patients with metabolic syndrome were included in the study. The study group (30 subjects with the mean age of 41.0?11 years, 23...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marina Fedorovna Kalashnikova, Vera Uchamprina, Tatiana Ivanovna Romantsova, Andrey Nikolaevich Gerasimov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	metabolic syndrome clinical and economic analysis abdominal obesity insulin resistance quality of life metformin orlistat Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/0c9097716c9a40dcafb1b5b73d4b2652
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c9097716c9a40dcafb1b5b73d4b2652
record_format	dspace
spelling	oai:doaj.org-article:0c9097716c9a40dcafb1b5b73d4b26522021-11-14T09:00:19ZClinical and economic analysis of the modern strategies for treating metabolic syndrome2072-03512072-037810.14341/DM20142116-125https://doaj.org/article/0c9097716c9a40dcafb1b5b73d4b26522014-07-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6408https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Objective. The objective of this study was to identify the ways to optimize therapy for metabolic syndrome through complex clinical and economic analysis. Methods. Sixty patients with metabolic syndrome were included in the study. The study group (30 subjects with the mean age of 41.0?11 years, 23 females (76.7%), 7 males (23.3%)) received pharmacotherapy for obesity (orlistat) and insulin resistance (metformin), lipid-lowering therapy and antihypertensive therapy, if needed. The control group (30 patients with the mean age of 43.4?9.5 years, 26 females (86.7%), 4 males (13.3%)) received lipid-lowering and antihypertensive therapy, if needed. All patients underwent clinical and laboratory examination, assessment of depression (Beck Depression Inventory) and evaluation of the quality of life using the SF-36 questionnaire at admission to the study and after 6 months of therapy. Complex clinical and economic analyses, including cost-effectiveness and cost-utility analyses and calculation of such indices as ?the incremental cost-effectiveness ratio? (ICER), LYG, QALY and ?net monetary benefit? (NMB), were conducted based on the results obtained. Results. Improvement of clinical and laboratory indicators and quality of life in the study group was more significant than that in the control group. The direct medical costs were 33,440.40 RUB for the study group and 18,878.50 RUB for the control group (for 6 months of therapy). The control group CER was 4,016.70, while the study group CER was 3,125.30; ICER was 2,430.90 RUB. LYG was equal to 0.7 and 2.3 years for the control and the study groups, respectively. The QALY measure for the control and study groups was 8.63 and 9.45, respectively. The weighted average total costs for the intended period of living was 498,745.00 RUB for the control group and 457,866.00 RUB for the study group. The control group CUR was 57,792.00 and 54,902.00 RUB/QALY without and with discounting, respectively, while in the study group they were 48,451.00 and 46,029.00 RUB/QALY, respectively. The NMB for the control group amounted to 10,790,910.00 and 10,815,840.00 RUB without and with discounting, respectively, while for the study group the values were 11,904,500.00 and 11,927,390.00 RUB. Conclusions. The results of clinical and economic analysis show that treatment of the metabolic syndrome, including pharmacotherapy of obesity and insulin resistance, should be prioritized over mere medical advisory and lifestyle modifications.Marina Fedorovna KalashnikovaVera UchamprinaTatiana Ivanovna RomantsovaAndrey Nikolaevich GerasimovEndocrinology Research Centrearticlemetabolic syndromeclinical and economic analysisabdominal obesityinsulin resistancequality of lifemetforminorlistatNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 2, Pp 116-125 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	metabolic syndrome clinical and economic analysis abdominal obesity insulin resistance quality of life metformin orlistat Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	metabolic syndrome clinical and economic analysis abdominal obesity insulin resistance quality of life metformin orlistat Nutritional diseases. Deficiency diseases RC620-627 Marina Fedorovna Kalashnikova Vera Uchamprina Tatiana Ivanovna Romantsova Andrey Nikolaevich Gerasimov Clinical and economic analysis of the modern strategies for treating metabolic syndrome
description	Objective. The objective of this study was to identify the ways to optimize therapy for metabolic syndrome through complex clinical and economic analysis. Methods. Sixty patients with metabolic syndrome were included in the study. The study group (30 subjects with the mean age of 41.0?11 years, 23 females (76.7%), 7 males (23.3%)) received pharmacotherapy for obesity (orlistat) and insulin resistance (metformin), lipid-lowering therapy and antihypertensive therapy, if needed. The control group (30 patients with the mean age of 43.4?9.5 years, 26 females (86.7%), 4 males (13.3%)) received lipid-lowering and antihypertensive therapy, if needed. All patients underwent clinical and laboratory examination, assessment of depression (Beck Depression Inventory) and evaluation of the quality of life using the SF-36 questionnaire at admission to the study and after 6 months of therapy. Complex clinical and economic analyses, including cost-effectiveness and cost-utility analyses and calculation of such indices as ?the incremental cost-effectiveness ratio? (ICER), LYG, QALY and ?net monetary benefit? (NMB), were conducted based on the results obtained. Results. Improvement of clinical and laboratory indicators and quality of life in the study group was more significant than that in the control group. The direct medical costs were 33,440.40 RUB for the study group and 18,878.50 RUB for the control group (for 6 months of therapy). The control group CER was 4,016.70, while the study group CER was 3,125.30; ICER was 2,430.90 RUB. LYG was equal to 0.7 and 2.3 years for the control and the study groups, respectively. The QALY measure for the control and study groups was 8.63 and 9.45, respectively. The weighted average total costs for the intended period of living was 498,745.00 RUB for the control group and 457,866.00 RUB for the study group. The control group CUR was 57,792.00 and 54,902.00 RUB/QALY without and with discounting, respectively, while in the study group they were 48,451.00 and 46,029.00 RUB/QALY, respectively. The NMB for the control group amounted to 10,790,910.00 and 10,815,840.00 RUB without and with discounting, respectively, while for the study group the values were 11,904,500.00 and 11,927,390.00 RUB. Conclusions. The results of clinical and economic analysis show that treatment of the metabolic syndrome, including pharmacotherapy of obesity and insulin resistance, should be prioritized over mere medical advisory and lifestyle modifications.
format	article
author	Marina Fedorovna Kalashnikova Vera Uchamprina Tatiana Ivanovna Romantsova Andrey Nikolaevich Gerasimov
author_facet	Marina Fedorovna Kalashnikova Vera Uchamprina Tatiana Ivanovna Romantsova Andrey Nikolaevich Gerasimov
author_sort	Marina Fedorovna Kalashnikova
title	Clinical and economic analysis of the modern strategies for treating metabolic syndrome
title_short	Clinical and economic analysis of the modern strategies for treating metabolic syndrome
title_full	Clinical and economic analysis of the modern strategies for treating metabolic syndrome
title_fullStr	Clinical and economic analysis of the modern strategies for treating metabolic syndrome
title_full_unstemmed	Clinical and economic analysis of the modern strategies for treating metabolic syndrome
title_sort	clinical and economic analysis of the modern strategies for treating metabolic syndrome
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/0c9097716c9a40dcafb1b5b73d4b2652
work_keys_str_mv	AT marinafedorovnakalashnikova clinicalandeconomicanalysisofthemodernstrategiesfortreatingmetabolicsyndrome AT verauchamprina clinicalandeconomicanalysisofthemodernstrategiesfortreatingmetabolicsyndrome AT tatianaivanovnaromantsova clinicalandeconomicanalysisofthemodernstrategiesfortreatingmetabolicsyndrome AT andreynikolaevichgerasimov clinicalandeconomicanalysisofthemodernstrategiesfortreatingmetabolicsyndrome
_version_	1718429508574380032

Clinical and economic analysis of the modern strategies for treating metabolic syndrome

Ejemplares similares